YD Bio Limited (Nasdaq:YDES), a US-based biotechnology company focused on DNA methylation-based cancer detection technology and ophthalmologic innovations, on Friday confirmed the completion of its business combination with Breeze Holdings Acquisition Corp, a publicly traded special purpose acquisition company.

Effective from 29 August 2025, YD Bio's ordinary shares and warrants will trade on Nasdaq Global Market under the ticker symbols 'YDES' and 'YDESW', respectively. The transaction was approved by Breeze shareholders at an extraordinary general meeting held on 14 August 2025.

YD Bio also announced that the previously announced PIPE offering closed, in full, contemporaneously with the closing of the business combination. The proceeds of the PIPE offering together with the cash released to the company from the trust for the benefit of the former Breeze shareholders, after satisfaction of all business combination closing-related expenses, is expected to yield more than USD11.5m to fund YD Bio's future operations.